
Creyon Bio
Pioneering pre-clinical firm revolutionizing oligonucleotide-based drug development for on-demand medicines.

Pioneering pre-clinical firm revolutionizing oligonucleotide-based drug development for on-demand medicines.
creyonbio.comCrawled Oct 14, 2026
The page covers Creyon’s partnerships, scientific milestones, company updates, and media coverage.
Redefining hope through RNA therapies, Creyon develops tissue-specific, RNA-targeted medicines designed to improve safety, efficacy, and patient experience.
Creyon provides information about its AI-driven RNA therapeutics and accepts investor and partner inquiries, media requests, and general inquiries.
Creyon is a drug development company enabling tissue specific delivery of RNA therapies designed to improve safety, efficacy, and patient experience in immunology, central nervous system (CNS), and neuromuscular disease.
Creyon’s privacy policy outlines how the company collects, uses, and protects personal information across its website and services.
Creyon Bio’s deal with Lilly provides for up to $1 billion in payments for research on RNA-targeting drugs. The article corroborates details about the collaboration’s economics, leadership, and clinical plans.
May 2025 · DCVCNews article
Creyon Bio enters a global licensing and multi-target RNA-oligo therapy development collaboration with Lilly. The agreement includes upfront cash, equity, and downstream milestones.
Apr 2025 · CreyonNews article
Independent coverage of Creyon Bio appointing Serge Messerlian as chief executive officer to advance AI-driven oligonucleotide drug development.
Apr 2025 · Discover PharmaNews article
Creyon Bio presents a clinical proof of concept involving TNPO2 antisense and describes its rapid AI-enabled engineering of oligonucleotide medicines during an oral session at ASGCT’s 27th Annual Meeting.
May 2024 · GlobeNewswireNews article